Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers

Noritaka Ariyoshi, Masami Miyamoto, Yuri Umetsu, Hideo Kunitoh, Hirotoshi Dosaka-Akita, Yu ichi Sawamura, Jun Yokota, Nobuo Nemoto, Kunio Sato, Tetsuya Kamataki

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Cytochrome P450 2A6 (CYP2A6) is the principal enzyme involved in the metabolic activation of tobacco-specific nitrosamines to their ultimate carcinogenic forms and metabolism of nicotine. We investigated the effects of the CYP2A6*4, an entire CYP2A6 gene deletion-type polymorphism, on lung cancer risk and daily cigarette consumption in Japanese male smokers via a hospital-based case control study. The frequency of the CYP2A6*4 variant was compared in 370 lung cancer patients and 380 control smokers. A markedly reduced adjusted odds ratio for lung cancer risk, 0.23 [95% confidence interval, 0.08-0.67], was seen in the group with homozygous deletion (*4/*4) when the odds ratio for a group with homozygous wild (*1A/*1A) was defined to be 1.00 by logistic regression. The subjects with lung cancer were additionally divided into three groups according to the histological classification of the cancer and examined for an association with the CYP2A6 polymorphism. The *4/*4 genotype was not found in patients with squamous cell carcinoma (0 of 105) or small cell carcinoma (0 of 44), indicating that subjects with the *4/*4 genotype have low risk for lung cancers, particularly those caused by tobacco smoke. Furthermore, a significant reduction of daily cigarette consumption was observed in smokers with the *4/*4 genotype, suggesting a possibility that complete lack of CYP2A6 appeared to affect the smoking behavior. These data suggest that male smokers possessing the *1A/*1A genotype have higher risk for tobacco-induced lung cancers.

Original languageEnglish
Pages (from-to)890-894
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number9
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Cytochrome P-450 Enzyme System
Tobacco
Lung Neoplasms
Genotype
Genes
Tobacco Products
Odds Ratio
Nitrosamines
Small Cell Carcinoma
Gene Deletion
Nicotine
Smoke
Case-Control Studies
Squamous Cell Carcinoma
Logistic Models
Smoking
Confidence Intervals
Enzymes
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y. I., ... Kamataki, T. (2002). Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiology Biomarkers and Prevention, 11(9), 890-894.

Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. / Ariyoshi, Noritaka; Miyamoto, Masami; Umetsu, Yuri; Kunitoh, Hideo; Dosaka-Akita, Hirotoshi; Sawamura, Yu ichi; Yokota, Jun; Nemoto, Nobuo; Sato, Kunio; Kamataki, Tetsuya.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 9, 2002, p. 890-894.

Research output: Contribution to journalArticle

Ariyoshi, N, Miyamoto, M, Umetsu, Y, Kunitoh, H, Dosaka-Akita, H, Sawamura, YI, Yokota, J, Nemoto, N, Sato, K & Kamataki, T 2002, 'Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers', Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 9, pp. 890-894.
Ariyoshi, Noritaka ; Miyamoto, Masami ; Umetsu, Yuri ; Kunitoh, Hideo ; Dosaka-Akita, Hirotoshi ; Sawamura, Yu ichi ; Yokota, Jun ; Nemoto, Nobuo ; Sato, Kunio ; Kamataki, Tetsuya. / Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. In: Cancer Epidemiology Biomarkers and Prevention. 2002 ; Vol. 11, No. 9. pp. 890-894.
@article{7de768b4478849fabe8c088737606854,
title = "Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers",
abstract = "Cytochrome P450 2A6 (CYP2A6) is the principal enzyme involved in the metabolic activation of tobacco-specific nitrosamines to their ultimate carcinogenic forms and metabolism of nicotine. We investigated the effects of the CYP2A6*4, an entire CYP2A6 gene deletion-type polymorphism, on lung cancer risk and daily cigarette consumption in Japanese male smokers via a hospital-based case control study. The frequency of the CYP2A6*4 variant was compared in 370 lung cancer patients and 380 control smokers. A markedly reduced adjusted odds ratio for lung cancer risk, 0.23 [95{\%} confidence interval, 0.08-0.67], was seen in the group with homozygous deletion (*4/*4) when the odds ratio for a group with homozygous wild (*1A/*1A) was defined to be 1.00 by logistic regression. The subjects with lung cancer were additionally divided into three groups according to the histological classification of the cancer and examined for an association with the CYP2A6 polymorphism. The *4/*4 genotype was not found in patients with squamous cell carcinoma (0 of 105) or small cell carcinoma (0 of 44), indicating that subjects with the *4/*4 genotype have low risk for lung cancers, particularly those caused by tobacco smoke. Furthermore, a significant reduction of daily cigarette consumption was observed in smokers with the *4/*4 genotype, suggesting a possibility that complete lack of CYP2A6 appeared to affect the smoking behavior. These data suggest that male smokers possessing the *1A/*1A genotype have higher risk for tobacco-induced lung cancers.",
author = "Noritaka Ariyoshi and Masami Miyamoto and Yuri Umetsu and Hideo Kunitoh and Hirotoshi Dosaka-Akita and Sawamura, {Yu ichi} and Jun Yokota and Nobuo Nemoto and Kunio Sato and Tetsuya Kamataki",
year = "2002",
language = "English",
volume = "11",
pages = "890--894",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers

AU - Ariyoshi, Noritaka

AU - Miyamoto, Masami

AU - Umetsu, Yuri

AU - Kunitoh, Hideo

AU - Dosaka-Akita, Hirotoshi

AU - Sawamura, Yu ichi

AU - Yokota, Jun

AU - Nemoto, Nobuo

AU - Sato, Kunio

AU - Kamataki, Tetsuya

PY - 2002

Y1 - 2002

N2 - Cytochrome P450 2A6 (CYP2A6) is the principal enzyme involved in the metabolic activation of tobacco-specific nitrosamines to their ultimate carcinogenic forms and metabolism of nicotine. We investigated the effects of the CYP2A6*4, an entire CYP2A6 gene deletion-type polymorphism, on lung cancer risk and daily cigarette consumption in Japanese male smokers via a hospital-based case control study. The frequency of the CYP2A6*4 variant was compared in 370 lung cancer patients and 380 control smokers. A markedly reduced adjusted odds ratio for lung cancer risk, 0.23 [95% confidence interval, 0.08-0.67], was seen in the group with homozygous deletion (*4/*4) when the odds ratio for a group with homozygous wild (*1A/*1A) was defined to be 1.00 by logistic regression. The subjects with lung cancer were additionally divided into three groups according to the histological classification of the cancer and examined for an association with the CYP2A6 polymorphism. The *4/*4 genotype was not found in patients with squamous cell carcinoma (0 of 105) or small cell carcinoma (0 of 44), indicating that subjects with the *4/*4 genotype have low risk for lung cancers, particularly those caused by tobacco smoke. Furthermore, a significant reduction of daily cigarette consumption was observed in smokers with the *4/*4 genotype, suggesting a possibility that complete lack of CYP2A6 appeared to affect the smoking behavior. These data suggest that male smokers possessing the *1A/*1A genotype have higher risk for tobacco-induced lung cancers.

AB - Cytochrome P450 2A6 (CYP2A6) is the principal enzyme involved in the metabolic activation of tobacco-specific nitrosamines to their ultimate carcinogenic forms and metabolism of nicotine. We investigated the effects of the CYP2A6*4, an entire CYP2A6 gene deletion-type polymorphism, on lung cancer risk and daily cigarette consumption in Japanese male smokers via a hospital-based case control study. The frequency of the CYP2A6*4 variant was compared in 370 lung cancer patients and 380 control smokers. A markedly reduced adjusted odds ratio for lung cancer risk, 0.23 [95% confidence interval, 0.08-0.67], was seen in the group with homozygous deletion (*4/*4) when the odds ratio for a group with homozygous wild (*1A/*1A) was defined to be 1.00 by logistic regression. The subjects with lung cancer were additionally divided into three groups according to the histological classification of the cancer and examined for an association with the CYP2A6 polymorphism. The *4/*4 genotype was not found in patients with squamous cell carcinoma (0 of 105) or small cell carcinoma (0 of 44), indicating that subjects with the *4/*4 genotype have low risk for lung cancers, particularly those caused by tobacco smoke. Furthermore, a significant reduction of daily cigarette consumption was observed in smokers with the *4/*4 genotype, suggesting a possibility that complete lack of CYP2A6 appeared to affect the smoking behavior. These data suggest that male smokers possessing the *1A/*1A genotype have higher risk for tobacco-induced lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=0036716809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036716809&partnerID=8YFLogxK

M3 - Article

C2 - 12223434

AN - SCOPUS:0036716809

VL - 11

SP - 890

EP - 894

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -